CMS & FMQAI - Request Comments
On behalf of the Centers for Medicare & Medicaid Services (CMS), FMQAI invites all interested healthcare professionals, stakeholder organizations, and individuals to provide comments on the following two proposed adverse drug event quality measures:
1. CMS #701a - Adverse Drug Events: Hyperglycemia
Description: Average percentage of hyperglycemic hospital days for individuals with a diagnosis of diabetes mellitus, anti-diabetic drugs (except metformin) administered, or at least one elevated glucose level during the hospital stay.
2. CMS #701b - Adverse Drug Events: Hypoglycemia
Description: The Rate of hypoglycemic events following the administration of an anti-diabetic agent.
These measures are relevant to the clinical areas and/or topics of endocrinology, diabetes, pharmacology, patient safety, and health information technology. These measures are being developed under the CMS Medication Measures Special Innovation Project. The public comment period will be open from August 22, 2013, through September 6, 2013 (11:59 p.m. ET). All Feedback submitted within the public comment period will be reviewed and considered by the project's Technical Expert Panel.
Click here for additional information about the Medication Measures Special Innovation Project and the proposed quality measures.
To submit comments on the above-mentioned adverse drug event quality measures and to view the Measure Information Forms, please go to: http://www.surveymoney.com/s/GCMeasures
If you are interested in receiving information about a broader range of FDA topics, consider subscribing to the FDA Patient Network News, a twice monthly newsletter containing FDA-related information on a variety of topics, including new product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings, proposed regulatory guidances and opportunity to comment, and other information of interest to patients and patient advocates.
Subscriber Services:
Manage Preferences | Unsubscribe | Help with this service
| Stay Connected: | |||||||||||||
 |  |  |  |  |  | ||||||||
| This email was sent to buzzhairs.health@blogger.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
No comments:
Post a Comment